A Prospective, Phase 4, Multicenter, Open-label Pilot Study of Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid Gel for the Treatment of Volume Loss, Skin Laxity and Fine Lines

Clinical trial to assess the real-world effectiveness of Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid (HA) gel for the treatment of mild-to-moderate facial aging, including volume loss, fine lines, and skin laxity, following treatment administered using routine clinical injection techniques over the course of 60 days.

开始日期2026-03-01

申办/合作机构

Obagi Medical Products, Inc.

NCT07510620

/ Recruiting临床4期IIT

Prospective, Single Arm Clinical Trial for the Treatment of Dry Eyes Signs and Symptoms in Patients With Limited Tolerability of Contact Lens Wear

This research study is to see if using Lacrifill is safe, easy to use, and helpful for people who wear contact lenses but can't wear them comfortably for long. Specifically, the study aims to determine whether regular use of Lacrifill over a 2-3 month period can help people wear their contacts longer without discomfort and reduce signs and symptoms of dry eye.

开始日期2025-12-12

申办/合作机构

Nordic Pharma Group

RBR-8qcgzxw

/ Not yet recruiting临床4期IIT

Comparative study between Hyaluronic Acid and Corticosteroids in facet joints in the treatment of chronic low back pain: randomized clinical study

开始日期2025-05-01

申办/合作机构-

100 项与透明质酸相关的临床结果

登录后查看更多信息

100 项与透明质酸相关的转化医学

登录后查看更多信息

100 项与透明质酸相关的专利（医药）

登录后查看更多信息

6,852

项与透明质酸相关的文献（医药）

2026-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Evidence-based recommendations for the treatment of recurrent aphthous stomatitis: insights from an umbrella review

Review

作者: AlShehri, Bayan K. ; Alhomood, Khalid S. ; Abuhasna, Waad R. ; Al-Shamiri, Hashem M. ; Al-Maweri, Sadeq Ali ; Al-Aizari, Nader A. ; Alzahrani, Saeed R.

OBJECTIVE:

To compare the effectiveness and safety of pharmacological, physical, and complementary interventions for recurrent aphthous stomatitis (RAS) across clinically relevant outcomes.

METHODS:

This umbrella review was conducted according to PRISMA and Cochrane guidance and registered in PROSPERO (CRD42024594292). PubMed, Scopus, and the Cochrane Library were searched through August 2025. Eligible studies were systematic reviews, meta-analyses, or network meta-analyses evaluating treatments for RAS. Methodological quality was assessed using AMSTAR 2, and overlap of primary studies was quantified using the corrected covered area.

RESULTS:

A total of 41 reviews were included. Topical corticosteroids and low-level laser therapy consistently reduced pain and shortened healing time, although evidence for recurrence prevention was limited. Hyaluronic acid and herbal agents demonstrated favorable short-term efficacy with good safety profiles. Systemic agents such as colchicine and thalidomide showed benefit in severe or refractory RAS, but were constrained by the adverse effects and low-certainty evidence.

CONCLUSION:

Evidence supports topical corticosteroids, hyaluronic acid, and laser therapy for short-term symptom control in RAS, while systemic agents should be reserved for selected refractory cases.

2026-12-31·Future Science OA

Intra-articular injection of high versus low molecular weight hyaluronic acid in adhesive capsulitis; randomized trial

Article

作者: Mohebbi, Rezvaneh ; Mir, Mahshad ; Mohammadnezhad, Ghader ; Raeissadat, Seyed Ahmad ; Parhizgar, Alireza ; Esmaily, Hadi

BACKGROUND:

Adhesive capsulitis (AC) is a chronic inflammatory condition with limited range of motion (ROM) in the glenohumeral joint. The main goals in managing AC are pain reduction and returning joint function. Intra-articular hyaluronic acid (HA) has been considered a safe modality in AC. This study compared the effectiveness of intra-articular injection of low molecular weight (LMW) with high molecular weight (HMW) HA in patients with AC.

METHODS:

Fifty-six patients with AC were randomized in this triple-blinded clinical trial. All underwent standard physical therapy. The outcomes were visual analog scale (VAS), Oxford shoulder score (OSS), active ROM, and patient satisfaction at 4, 12, and 24 weeks.

RESULTS:

No significant differences were detected in between-group variables at baseline. Both groups showed marked improvement in VAS, OSS, and ROM over time. At four weeks LMW-HA group had lower pain (P = 0.049). Conversely, the trend of VAS at 12-week and 24-week endpoints favors HMW-HA (Baseline to endpoint: -5.48 ± 1.68 and -3.91 ± 1.31 reduction in VAS as the primary outcome, P < 0.001). Satisfaction had significantly improved in both groups.

CONCLUSION:

HMW-HA was associated with greater pain reduction and functional improvement compared with LMW-HA.

TRIAL REGISTRATION:

The trial protocol was registered at the Iranian Registry of Clinical Trials (IRCT), a WHO Primary Register setup (registration No: IRCT20170608034390N4; First registration date: 01/01/2020).

2026-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Midface volumization and skin quality enhancement with a hyaluronic acid–polynucleotide hybrid filler: a 24-week prospective open-label study

Article

作者: Park, Kui Young ; Youn, Choon Shik ; Lee, So Young

BACKGROUND:

Facial aging is characterized by midface volume loss from structural and dermal atrophy.

OBJECTIVES:

To evaluate the efficacy and safety of a hyaluronic acid-polynucleotide (HA-PN) hybrid filler for temporary restoration of anteromedial cheek volume.

METHODS:

In this single-center, open-label trial, 15 adults with moderate-to-severe anteromedial cheek volume loss (Mid-Face Volume Deficit Scale [MFVDS] score ≥ 3) received up to 1 mL HA-PN hybrid filler per side. Evaluations at baseline and weeks 4, 12, and 24 comprised blinded photographic MFVDS rating (primary endpoint: ≥1-grade improvement at week 4), GAIS (Global Aesthetic Improvement Scale) score, participant satisfaction, transepidermal water loss, skin hydration, elasticity, and adverse events.

RESULTS:

All participants completed the study without serious adverse events. MFVDS scores improved significantly at week 4 and remained improved through weeks 12 and 24. GAIS and satisfaction scores paralleled these gains. Transepidermal water loss decreased and hydration increased over time, and Cutometer parameters (R2 R5 R7) showed progressive improvements in elasticity, indicating enhanced skin quality along with midface volumization.

CONCLUSIONS:

The HA-PN hybrid filler demonstrated improvements in midface volume restoration with concurrent improvements in skin barrier function, hydration, and elasticity, and was well tolerated over 24 weeks within the constraints of the study design.

200

项与透明质酸相关的新闻（医药）

2026-05-22

·淮阳祝氏骨科医院

我院开展富血小板血浆（PRP）技术。

富血小板血浆（PRP）技术在膝关节疾病中的临床应用与价值膝关节作为人体负重最大、活动最频繁的关节，极易因劳损、退变、外伤引发疼痛、肿胀、活动受限等问题，其中膝关节骨关节炎、软骨损伤、滑膜炎等是临床高发骨关节疾病。传统保守治疗以止痛、抗炎、对症缓解为主，难以修复受损软骨组织；手术治疗创伤大、恢复期长，很多中老年患者及轻症患者难以接受。富血小板血浆（PRP）作为再生医学核心技术之一，凭借自体取材、安全微创、靶向修复的独特优势，已成为目前膝关节退行性、损伤性疾病的优选治疗方案，广泛应用于骨科临床诊疗。一、PRP技术的核心原理与优势富血小板血浆是通过离心技术，对患者自身外周血液进行分层提纯，去除红细胞、白细胞等杂质，获得的高浓度血小板血浆，其血小板浓度为正常血液的3-8倍，同时富含多种活性生长因子，是人体天然的“组织修复原液”。 PRP治疗全程采用自体血液取材，从根源避免了异体生物制剂可能引发的排异反应、过敏风险及交叉感染问题，安全性极高。区别于药物仅能抗炎止痛的对症治疗模式，PRP不依赖外源药物，通过激活血小板释放血小板衍生生长因子、转化生长因子、血管内皮生长因子等十余种活性因子，精准作用于受损膝关节组织，实现抗炎消肿、修复软骨、改善关节微环境、延缓关节退变的多重治疗效果，打破了传统治疗“只缓解、不修复”的局限。二、PRP治疗膝关节疾病的作用机制膝关节各类病变的核心病理，集中于软骨磨损退变、滑膜慢性炎症、韧带肌腱微损伤、关节代谢紊乱，PRP通过多靶点机制实现精准修复，适配膝关节病变的病理特点。 1. 修复受损软骨组织：膝关节软骨无血管、无神经，自我修复能力极差，一旦磨损难以自愈。PRP中的高活性生长因子可刺激软骨细胞增殖分化，促进Ⅱ型胶原蛋白、蛋白多糖合成，修复磨损、缺损的关节软骨，填补软骨微小创面，延缓软骨变薄、钙化进程，从根本改善关节磨损问题。 2. 强效抑制慢性炎症：膝关节长期劳损、退变会引发持续性无菌性炎症，释放IL-1β、TNF-α等炎症因子，导致反复肿痛、积液。PRP可精准下调促炎因子表达，抑制滑膜异常增生和炎性渗出，消除关节慢性炎症，减少关节积液生成，缓解持续性关节肿痛。 3. 修复软组织微损伤：针对膝关节周围肌腱、韧带、滑膜的微小撕裂与劳损损伤，PRP可促进纤维组织再生，加速软组织创面愈合，增强关节周围软组织稳定性，改善关节松弛、发力疼痛等问题。 4. 调节关节微环境：PRP可改善膝关节局部血液循环，优化关节液代谢，减少软骨骨质增生诱因，延缓膝关节骨关节炎的进展速度，有效降低疾病复发率。三、PRP在膝关节疾病中的主要临床应用结合国内外最新临床研究与骨科诊疗指南，PRP主要适用于轻中度膝关节病变，适配绝大多数非手术膝关节疾病，临床应用场景精准且广泛。（一）轻中度膝关节骨关节炎这是PRP最核心、最成熟的应用领域。针对Kellgren–LawrenceⅠ-Ⅲ级轻中度膝骨关节炎患者，尤其适合60岁以下、软骨轻中度磨损、伴随反复肿痛、活动后加重的患者。大量随机对照临床试验证实，PRP治疗可显著降低患者VAS疼痛评分、WOMAC关节功能评分，6-12个月随访显示，60%-70%患者的关节屈伸、行走、上下楼梯功能得到明显改善。相较于透明质酸，PRP在关节功能修复上优势显著；相较于激素封闭治疗，PRP无软骨损伤、骨质疏松等副作用，远期疗效更稳定，可有效延缓骨关节炎进展，推迟甚至避免关节置换手术。（二）膝关节软骨损伤针对运动损伤、日常劳损导致的膝关节局灶性软骨缺损、软骨软化、软骨磨损，尤其是中青年运动人群的软骨微损伤，PRP是首选微创修复方案。传统治疗无法修复缺损软骨，而PRP可直接作用于损伤部位，激活软骨再生修复机制，改善关节卡顿、弹响、负重疼痛等症状，帮助患者恢复正常运动与生活功能，避免微小软骨损伤进展为大面积退变。（三）慢性膝关节滑膜炎、关节积液对于长期劳损、退变引发的顽固性无菌性滑膜炎、反复关节积液，常规抽液、抗炎治疗易复发，而PRP可从根源抑制滑膜慢性炎症，修复受损滑膜组织，恢复滑膜正常分泌代谢功能，彻底解决关节反复积液、肿胀疼痛的问题，复发率远低于传统治疗。（四）膝关节软组织劳损与术后康复适用于髌腱炎、鹅足腱炎、膝关节周围肌腱韧带慢性劳损，同时可作为膝关节微创手术后的辅助康复治疗。术后注射PRP可加速创面软组织愈合，减轻术后粘连、肿痛，缩短康复周期，提升手术整体疗效。四、标准化临床治疗方案根据2025年最新Meta分析及临床共识，最优治疗方案已形成标准化体系，可保障临床疗效最大化： 1. 最佳血小板浓度：600–900×10⁹/L，该浓度区间修复活性最强、疗效最稳定； 2. 治疗疗程：推荐序贯注射方案，共3-5次注射，每次间隔2周，序贯治疗的抗炎、修复效果显著优于单次注射，可有效降低炎症因子水平、促进软骨修复； 3. 适用周期：单次疗程疗效可维持1-2年，轻症患者规范治疗后可实现临床治愈，中重度患者可显著延缓病情进展。五、PRP与传统膝关节治疗的疗效对比 1. 对比激素封闭治疗：激素止痛见效快，但仅能短期抗炎，反复注射会损伤软骨、诱发骨质疏松、增加关节感染风险，远期副作用大；PRP止痛速度温和，无任何毒副作用，兼具修复功效，远期疗效更持久。 2. 对比透明质酸注射：透明质酸仅能润滑关节、临时缓冲磨损，无组织修复能力；PRP润滑关节的同时可修复受损软骨、消除慢性炎症，在关节功能改善上显著优于透明质酸，联合使用可实现疗效叠加。 3. 对比常规理疗康复：针灸、理疗、药物仅能缓解肌肉痉挛、表面疼痛，无法修复深层软骨及滑膜损伤，易反复发病；PRP直击病变根源，实现“止痛+修复+维稳”三重效果，复发率极低。六、PRP治疗的优势与临床局限核心优势 1. 安全性极高：自体取材、无排异、无药物副作用、无感染风险，老少皆宜，适配不耐受药物、惧怕手术的中老年患者； 2. 微创无痛：全程细针注射、创口微小、无需住院、随治随走，不影响正常生活与工作； 3. 标本兼治：区别于传统对症治疗，可修复受损软骨、滑膜组织，从根源改善膝关节病变； 4. 适配广泛：覆盖绝大多数轻中度膝关节疾病，可单独治疗，也可与理疗、微创手术联合应用。临床局限 PRP疗效存在明确分级适配性，重度膝关节骨关节炎、关节严重畸形、大面积软骨完全磨损、关节间隙狭窄患者，单纯PRP治疗效果有限，需结合手术综合治疗。同时，目前PRP制备方案、激活方式尚未完全统一，不同医疗机构的制备工艺差异，会轻微影响治疗效果。七、总结与临床展望在膝关节疾病的阶梯化治疗体系中，PRP技术填补了**“传统保守治疗与手术治疗”之间的空白**，是再生医学在骨科领域的突破性应用。其安全、微创、可修复、长效稳定的特点，完美适配轻中度膝关节炎、软骨损伤、慢性滑膜炎患者的诊疗需求，现已成为国内外骨科指南推荐的一线微创治疗方案。

2026-05-21

·Business Wire

Teleflex Showcases New Clinical Data at Leading Urological Congresses Highlighting Patient Experience Advantages of the UroLift™ System and Long-Term Toxicity Reduction with Barrigel™ Rectal Spacer

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the Interventional Urology Business Unit has released new clinical data across two major urological congresses, reinforcing the value of the UroLift™ System and Barrigel™ rectal spacer in improving patient-centered outcomes across benign prostatic hyperplasia (BPH) and prostate cancer care. Teleflex Interventional Urology innovations help urologists treat medical needs while ensuring patients can recover and maintain their quality of life long after treatment. In parallel with Teleflex’s long-term strategy to significantly streamline the Teleflex business and narrow focus to the critical care and high-acuity hospital end-markets, the company’s Interventional Urology business unit continues to drive clinical value as it prepares for its divestiture in the second half of 2026. Data presented at the 2026 American Urological Association (AUA) Annual Meeting in Washington, DC. May 15 – 18 and the European Society for Radiotherapy & Oncology (ESTRO) Congress held in Stockholm May 15 – 19 highlight early patient experience following BPH treatment1 with the UroLift™ System and sustained reductions in radiation-associated toxicity for prostate cancer patients who received Barrigel™ rectal spacer.2 CLEAR RCT: First Head-to-Head Comparison of Minimally Invasive Surgical Therapies (MISTs) Demonstrates Favorable Early Patient Experience with the UroLift™ System* At AUA 2026, Dr. Bilal Chughtai**, a urologist with Northwell Health, Garden City, N.Y., presented 12-month findings from the CLEAR (Comparing UroLift™ Experience Against Rezūm™) randomized controlled trial, the first prospective, multicenter, head-to-head RCT comparing MISTs for BPH.1 The study evaluated key endpoints including catheter independence, symptom improvement, patient experience, and sexual function.1 Key study endpoints of the study: Catheter independence from day three through day seven was significantly better among UroLift™ System patients compared to Rezūm™ patients, with 3 percent requiring catheter versus 20 percent (p=.02) respectively 1 Early patient experience was better for the UroLift™ System patients compared to Rezūm™ patients 1 UroLift™ System and Rezūm™ subjects had similar durability through 12 months 1 Patients’ sexual function † was preserved through 12 months with the UroLift™ System 1 “What stands out in our CLEAR RCT study is the consistency of the early patient experience advantages with the UroLift™ System, particularly catheter independence, rapid recovery, and preservation of sexual function, which are critical factors for both patients and physicians when selecting a treatment approach,” said Dr. Bilal Chughtai**, a urologist practicing in Syosset, N.Y. Barrigel™ Rectal Spacer Three-Year Data Demonstrate Sustained Reduction in Radiation-Associated Toxicity* At ESTRO 2026, new three-year outcomes presented by Dr. Martin King** highlighted the long-term safety and effectiveness of Barrigel™ rectal spacer.2 Key endpoints of the study: Patients in the Barrigel™ rectal spacer arm of the study experienced a continued Grade 2+ toxicity benefit sustained through three years. Zero percent of the Barrigel™ rectal spacer patients experienced Grade 2+ toxicity versus 10 percent in the control arm 2 Fewer patients with greater than one centimeter of apical spacing had a decline in bowel quality of life at 36 months versus control 2 These results demonstrate a durable benefit for the Barrigel™ rectal spacer subjects sustained through three years, reinforcing the role of rectal spacing in protecting bowel function during and after radiation therapy.2 “The three-year data further validate the clinical value of Barrigel™ rectal spacer, demonstrating sustained and clinically meaningful reductions in gastrointestinal toxicity,” said Martin King**, MD, PhD, presenter and radiation oncologist with the Dana-Farber Brigham Cancer Center, Harvard Medical School Associate Professor of Radiation Oncology. “Reducing radiation treatment-related toxicity is essential for prostate cancer patients, and these findings support the continued adoption of rectal spacing as a standard component of care.” 2 “These data reflect our prostate health leadership and ongoing commitment to advancing evidence-based, patient-centered solutions across the urology care continuum,” said Travis Gay, President and General Manager, Interventional Urology, Teleflex. “From improving early recovery and preserving sexual function in BPH patients with the UroLift™ System to delivering durable protection against radiation-related rectal toxicity with Barrigel™ spacer, we are focused on technologies that meaningfully improve patients’ lives.” About the UroLift™ System The UroLift™ System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100cc in men 45 years or older (50 years outside U.S.). The UroLift™ System permanent implants, which can be delivered during an outpatient procedure,3 relieve prostate obstruction without heating, cutting, destruction of, or removing prostate tissue. The UroLift™ System can be used to treat a broad spectrum of anatomies, including obstructive median lobe.4,5 It is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction.†6-7 A study conducted over five years showed a low retreatment rate of about 2 to 3 percent per year, or a total of 13.6 percent over the course of the study, demonstrating UroLift™ System durability.8 Most common side effects are temporary and can include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence.9 Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. The prostatic urethral lift procedure (using the UroLift™ System) is recommended for the treatment of BPH in both the 2021 American Urological Association and 2022 European Association of Urology clinical guidelines. More than 500,000 men have been treated with the UroLift™ System in select markets worldwide.10 Learn more at www.UroLift.com. UroLift System Important Safety Information The UroLift™ System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men 45 years or older with prostates ≤100 cc. Contraindicated in men with current gross hematuria, urinary tract infection, urinary incontinence due to incompetent sphincter, and urethral conditions that prevent device insertion. Most common side effects are temporary and include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. Visit urolift.com. About Barrigel™ Rectal Spacer Barrigel™ rectal spacer is the first and only hyaluronic acid rectal spacer that separates the prostate from the rectum to protect the rectum during radiation therapy treatment for prostate cancer.11 Barrigel™ rectal spacer is made from Non-Animal Stabilized Hyaluronic Acid (NASHA).12 Hyaluronic acid is a substance naturally present in the human body and is highly biocompatible and fully absorbable. NASHA has a proven history of safety and efficacy in a wide variety of medical applications in men, women and children worldwide.13,14 Barrigel™ rectal spacer has been proven to significantly reduce unwanted side effects from prostate cancer radiation therapy11 and is cleared for rectal spacing in the United States, Australia, and Europe.15 Barrigel™ rectal spacer is indicated for prostate cancer patients with T1-T3b disease. For more information about Barrigel™ rectal spacer, please visit https://barrigel.com/hcp/barrigel-control-matters. Barrigel™ Rectal Spacer Important Safety Information Barrigel™ rectal spacer is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and, in creating this space, the intent is to reduce the radiation dose delivered to the anterior rectum. It is composed of biodegradable material and maintains space for the entire course of prostate radiotherapy treatment and is intended to be absorbed by the patient’s body over time. It should only be administered by qualified and properly trained physicians with experience in ultrasound guidance and injection techniques in the urogenital/pelvic area. Potential complications include but are not limited to: pain associated with the injection; needle penetration or injection of Barrigel rectal spacer into the bladder, prostate, rectal wall, rectum, urethra, or intravascularly; local inflammatory reactions; infection; urinary retention; rectal mucosal damage, ulcers, necrosis; bleeding; constipation; and rectal urgency. Contraindicated in prostate cancer patients with clinical stage T4 disease. Individual results may vary. Visit barrigel.com. Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. About Interventional Urology The Interventional Urology Business Unit is leading in prostate health by advancing clinical evidence, elevating education, and supporting physicians and patients. Our portfolio includes Barrigel™ rectal spacer for men seeking to reduce rectal side effects associated with prostate cancer radiation therapy, the UroLift™ System for men suffering from BPH symptoms, and Deflux™ injectable gel for children with grades II-V vesicoureteral reflux (VUR). Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. Barrigel, Deflux, and UroLift are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. © 2026 Teleflex Incorporated. All rights reserved. APM1495A *Studies sponsored by Teleflex. **Drs. Chughtai and King are paid consultants of Teleflex †No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study References Chughtai et al. J Urol 2026 King M, Chao M et al. Prospective Randomized Controlled Trial of Hyaluronic Acid Spacer for Hypofractionated Prostate Radiation Therapy: 3-Year Results. Presented at: European Society for Radiotherapy and Oncology 2026 Annual Congress; May 2026; Stockholm, Sweden. Proffered Paper 3623. Shore, Can J Urol 2014 Rukstalis, Prostate Cancer Prostatic Dis 2018 UroLift™ System Instructions for Use AUA BPH Guidelines 2003, 2020 McVary, Urology 2019 Roehrborn, Can J Urol 2017 Roehrborn, J Urol 2013 Management estimate based on product sales as of June 2024. Data on file. Teleflex Interventional Urology. Mariados NF, Orio PF III, King M et al. JAMA Oncol (2023)*,** Barrigel Injectable Gel Instructions for Use (2022) Svatos M, Chell E, Low DA et al. Med Phys (2024)*,** Restylane ® celebrates 25 years of natural-looking results with its signature line of hyaluronic acid fillers. 2021. Data on file Teleflex. 2025

临床结果放射疗法临床研究

2026-05-20

·泉心生物

干细胞 vs PRP vs 玻璃酸钠：三张“膝盖保养卡”，到底怎么选？

↑↑↑关注[泉心生物公众号]，最新消息不错过~ “医生让我打玻璃酸钠润滑一下，病友又说PRP效果更好，网上还看到干细胞能修复软骨——我这种情况，到底该先试哪个？”三种注射疗法，三条路线，各自宣传口径不同，患者夹在中间，往往越听越懵。今天这篇文章，就用一张表、一条路径图，帮你把这件事彻底理清。一、先搞清楚：三张“卡”的本质完全不同 1.玻璃酸钠——“润滑剂” 它的学名叫透明质酸钠，本身就是健康关节滑液的天然成分，作用原理：你关节里的滑液变稀了、变少了，我补充进去，恢复黏弹性，减少骨头之间的摩擦力。打个比方：就像给生锈的门轴喷上润滑油，让它在活动时不那么“嘎吱”作响。 2.PRP——“维修队集结号” PRP（富血小板血浆）是从你自己的静脉血中提取的。血液经过离心后，浓缩出富含生长因子的血小板血浆，再打进关节。工作逻辑是“唤醒自我修复”：释放大量生长因子，把局部的修复细胞调动起来，同时抑制关节里的炎症反应。 3.干细胞——“施工队”（间充质干细胞进入关节后）： ①自己分化为软骨需要的纤维软骨细胞 ②分泌生长因子和细胞外囊泡，把周围的“土著细胞”也招呼起来一起干活 ③调控关节内的炎症微环境，给修复创造一个不被干扰的“施工工地”。二、一张表看懂：五大维度拆解膝骨关节炎的注射治疗，本质上是根据关节磨损程度选择不同层级的干预手段。它们不是并列的选项，而是一套阶梯递进的逻辑：先润滑，再唤醒，最后重建。第一层：润滑（玻璃酸钠）——适用于KL 1-2级，软骨尚存，需求是“保养”。当关节间隙正常或仅轻度狭窄时，问题在于滑液变稀、摩擦增加。玻璃酸钠直接补充滑液的黏弹性，起效快（2-4周），一次疗程维持约6个月，单针费用200-1000元，且部分纳入医保，是性价比最高的基础保养。《中国膝骨关节炎关节腔注射治疗专家共识（2026）》将其定位为轻中度患者的首选注射方案。第二层：唤醒（PRP）——适用于KL 1-3级，磨损加重，需求是“启动修复”。当润滑已不够，软骨出现明显磨损但尚未磨尽时，需要动员自身的修复力量。PRP从自体血液浓缩血小板，释放生长因子抑制炎症、刺激软骨基质合成，起效稍慢（4-8周），疗效维持6-12个月，单次费用2000-8000元，多自费。2025年ESSKA-ORBIT共识推荐PRP优先于玻璃酸钠用于膝骨关节炎，因其临床获益更持久。对合并症无法手术的KL 4级患者仍可尝试，但预期效果有限。注射用生物制剂在膝关节骨性关节炎治疗中的应用：欧洲ESSKA-ORBIT共识指南。第一部分——血液来源的制品（富血小板血浆）第三层：重建（干细胞）——适用于KL 2-3级，保守治疗无效，需求是“组织再生”。当PRP仍无法满足，且关节间隙尚存时，间充质干细胞不仅能分泌修复因子，还能直接分化为纤维软骨细胞，参与结构重建。2025年ESSKA-ORBIT共识将其列为二线注射选择。起效最慢（2-3个月开始，6-12个月持续向好），但后劲最足：MRI T2值从38.5降至31.2，软骨质量提升可持续一年以上。博鳌乐城备案价约3.6万元/单膝，三甲医院临床试验路径免费但入组严格。若已达KL 4级，关节间隙消失，三类注射均不推荐，应优先评估关节置换。决策只看两步：先拍负重位X光片明确KL分级，再沿着“润滑→唤醒→重建”的阶梯往上走，走到哪一级，选哪张卡。不必在最轻时花最多的钱，也不要在磨尽时指望打针挽回。三、决策路径图：三步走到你的答案下面这张流程图，建议你对照自己的KL分级，逐级走一遍：路径解读： KL 1-2级，首次介入治疗——选玻璃酸钠。理由：此时软骨磨损尚轻，核心需求是润滑和保护，玻璃酸钠价格低、医保可报销、副作用小，是性价比最高的“基础保养”。 KL 2-3级，玻璃酸钠效果不好或想更进一步——上PRP。理由：这个阶段单纯润滑已不够，需要介入修复过程。PRP释放的生长因子可以在一定程度上促进软骨基质合成，且安全性数据充分。 KL 2-3级，PRP打过仍不满意，或经济条件允许追求更高天花板——评估干细胞。理由：干细胞是目前唯一具备直接“重建”能力的选项，但门槛也最高——需严格符合KL 2-3级、非手术治疗6个月无效等条件。 KL 4级——三条路都不推荐作为首选。关节间隙已经消失、骨头对骨头摩擦的情况下，注射治疗的收益极为有限。此时应优先评估关节置换手术时机，不要因为“害怕开刀”而把钱和时间花在效果不大的注射治疗上。补充：能不能联合使用？答案是：部分可以，但不是简单叠加。 2025年发表的一项临床分析专门比较了骨髓间充质干细胞分别联合HA（玻璃酸钠）和PRP的效果，结果发现：干细胞联合玻璃酸钠在疼痛改善和12个月MRI影像评分上均优于干细胞联合PRP，且关节退变进展更少。提示玻璃酸钠提供的“润滑微环境”可能更有利于干细胞的定植和分化。记住这条规则：PRP可以和玻璃酸钠“分时段”配合使用，但不建议在同一次注射中混合。干细胞如果需要联合辅助，目前的证据倾向于优先选择玻璃酸钠，但必须由具备资质的医疗机构评估执行。透明质酸与富血小板血浆作为辅助手段在膝关节骨性关节炎治疗中的效果比较：两项临床试验的分析结果四、结语：选卡之前，先看清自己站在哪三张“膝盖保养卡”，没有哪张是绝对最好的，只有哪张最适合你现在的阶段。去正规三甲医院骨科或运动医学科，拍一张负重位X光片，明确KL分级。在做选择之前，做三件事： 1.问自己一个问题：你追求的是“快”还是“远”？快，玻璃酸钠2-4周起效；远，干细胞12个月还在改善。两条路的时间代价和心态准备完全不同。 2.算一笔真实的账。玻璃酸钠一年两个疗程5000元，PRP一个疗程10000元，干细胞3.6万单次——不是比谁贵，而是算：在你的KL分级下，每花一块钱能换来多少个月的“能走能蹲不疼”。 3.选卡之前，先看清楚自己站在KL分级的哪一级。拍好片子，拿着这份对比表，去和你的骨科医生坐下来好好聊——你会发现，原来那些让你纠结好几个月的困惑，答案一直就在你的膝盖上。推荐阅读： 1.干细胞治疗膝骨关节炎：什么人适合做？一文讲清临床进展与合规路径 2.打算用干细胞改善膝盖？先别问“管不管用”，这份就诊小抄能帮你省下十几万 3.膝关节软骨修复，干细胞打完就完了？打后48小时别犯的5个错——停哪些药、怎么吃、如何练，一份完整的膝盖康复方案 4.干细胞治膝盖，用“自己的”还是“别人的”？一张表说清，少花冤枉钱 5.【点击收听】膝盖疼了那么久，原来可以不必“换关节” 参考来源：《中国膝骨关节炎关节腔注射治疗专家共识（2026版）》，中华骨科杂志 ESSKA-ORBIT共识Part 1（PRP）及Part 2（细胞治疗），Knee Surgery, Sports Traumatology, Arthroscopy, 2025 《间充质干细胞治疗膝骨关节炎和软骨缺损临床应用指南》T/CEAC 109-2025 《膝骨关节炎关节腔注射药物如何选择？——从激素到PRP》，2025年12月 Effect of Hyaluronic Acid Compared to Platelet-Rich Plasma as Adjuvants to Bone Marrow Mesenchymal Stem Cell Treatment of Knee Osteoarthritis, Diagnostics, 2025 博鳌乐城29项CGT项目清单及收费公示，2026年4月《协和医学杂志》：脐带间充质干细胞治疗膝骨关节炎研究进展，2025年第16卷第1期免责声明：本文内容由人工智能技术辅助生成，旨在进行客观中立的科普与信息分享，不构成任何形式的专业医疗诊断、治疗建议或用药指导；健康问题具有高度个体差异，请务必以医疗卫生机构的正式诊断及医嘱为准，严禁将本文作为自行诊疗依据，因依赖本文内容所引致的任何直接或间接后果本平台不予承担法律责任。文中配图源自公开合法渠道，仅作辅助说明之用，若相关著作权人认为存在侵权，请通过下方企业微信出示有效权属证明，我们将在核实后二十四（24）小时内予以删除、替换并致以诚挚歉意。

100 项与透明质酸相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08043	透明质酸	-	DB08818

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
膝关节炎	临床2期	-	-	2021-06-01
α1-抗胰蛋白酶缺乏症	临床1期	-	Actelion Pharmaceuticals Ltd.	-
哮喘	临床1期	-	Actelion Pharmaceuticals Ltd.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01066026 (CTgov)	临床2期	-	25	hyaluronic acid with metallic cannula or standard needle.+the new tool. (Metallic Cannula)	壓網淵窪願蓋簾簾鬱夢 = 壓顧膚築齋醖鹽齋觸鏇膚餘壓膚選廠壓願淵鏇 (簾構願蓋糧鹽鹹艱鹽齋, 鏇構願鬱艱觸艱範簾製 ~ 簾醖鏇鹽積餘鏇膚鬱獵) 更多	-	2020-09-09
				hyaluronic acid with metallic cannula or standard needle. (Standard Needle)	壓網淵窪願蓋簾簾鬱夢 = 獵餘製簾壓鏇膚鹹積鏇膚餘壓膚選廠壓願淵鏇 (簾構願蓋糧鹽鹹艱鹽齋, 齋衊遞醖繭齋壓夢鬱願 ~ 衊鬱衊鹽壓鏇繭鏇憲鹽) 更多
EBMT2020	N/A	造血干细胞移植	32	Hyaluronic Acid Bladder Instillation	醖醖鑰遞窪網齋繭遞鏇(襯製願衊鏇觸餘網願簾) = 積膚鬱衊選餘壓衊齋繭淵選鏇觸餘餘廠網製淵 (窪淵築鏇觸憲觸窪鑰鏇 ) 更多	-	2020-08-29
				Intravesical Hyaluronic Acid (Conventional Measures (hyperhydration, transfusion support, vesical irrigation))	夢簾鹹齋鏇廠膚衊衊鏇(餘願簾艱繭鬱蓋網襯襯) = 壓鹽遞蓋襯襯鬱膚範遞鹹艱選範積夢遞觸構夢 (鹹願築鹽鬱製鑰膚顧糧 )